[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-medullary-carcinoma-rmc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-medullary-carcinoma-rmc":18},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":4,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":4,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":15,"phases":4,"briefSummary":16,"conditions":17,"keywords":4,"overallStatus":20,"whyStopped":4,"lastUpdateSubmitDate":21,"lastUpdatePostDateStruct":22,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":25,"locationsCount":4},"100631594","compassionate-use-of-ubamatamab-100631594",false,"NCT07502716","Compassionate Use of Ubamatamab","Eligibility will be determined during the application review process.","EXPANDED_ACCESS","Provide Compassionate Use of Ubamatamab",[18,19],"Renal Medullary Carcinoma (RMC)","Epithelioid Sarcoma","AVAILABLE","2026-03-24",{"date":23,"type":24},"2026-03-31","ACTUAL",{"name":26,"class":27},"Regeneron Pharmaceuticals","INDUSTRY"]